TABLE 4.

Subgroup analyses of effect of glucagon‐like peptide‐1 receptor agonist on waist circumference

	No. studies	WMD	95% CI	I 2	P *	I 2 between groups	P **
Intervention duration						0%	0.72
>24 weeks	6	−3.22	−5.11, −1.33	79%	0.0002
≤24 weeks	3	−2.46	−6.12,1.20	41%	0.19
Control group						69.6%	0.07
Placebo	3	−4.53	−5.86, −3.21	23%	0.27
Active comparator drugs	6	−2.13	−4.37, −0.12	71%	0.005
Baseline BMI						86.7%	0.006
Obesity (>30 kg/m2)	6	−1.85	−3.79, 0.10	61%	0.02
Over weight (25–30 kg/m2)	3	−5.00	−6.14, −3.86	0%	0.84
Types of GLP‐1RA						0%	0.95
Liraglutide	7	−3.05	−4.93, −1.17	76%	0.0003
Exenatide	2	−3.18	−6.70, 0.33	45%	0.18

BMI, body mass index; CI, confidence interval; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; MD, mean difference; WC, waist circumference; WMD, weighted mean difference.

^* P‐value for heterogeneity within each subgroup.

^** P‐value for heterogeneity between subgroup.